Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 11/20 | 0.73 |
| ▸ | AURKA | O14965 | 7/20 | 0.73 |
| ▸ | JAK3 | P52333 | 6/20 | 0.73 |
| ▸ | JAK2 | O60674 | 6/20 | 0.73 |
| ▸ | IGF1R | P08069 | 3/20 | 0.73 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.73 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.73 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.73 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.73 |
| ▸ | FLT1 | P17948 | 1/20 | 0.73 |
| ▸ | LTK | P29376 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.73 |
| ▸ | CLK2 | P49760 | 1/20 | 0.73 |
| ▸ | CDK7 | P50613 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434985 | 1.00 | NTRK1 (0.73) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL31060183 | 1.00 | NTRK1 (0.73) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL18281508 | 1.00 | NTRK1 (0.73) | NTRK1AURKAJAK3JAK2IGF1R | |
| Phosphoric Acid SCHEMBL3041888 | 0.95 | NTRK1 (0.66) | NTRK1AURKAJAK3JAK2IGF1R | |
| Maleic Acid SCHEMBL4904780 | 0.93 | NTRK1 (0.63) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL3034183 | 0.92 | NTRK1 (0.71) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL3041951 | 0.91 | NTRK1 (0.69) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL17433341 | 0.91 | NTRK1 (0.59) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL588783 | 0.89 | JAK3 (0.57) | NTRK1AURKAJAK3JAK2IGF1R | |
| SCHEMBL3036561 | 0.89 | JAK2 (0.58) | NTRK1AURKAJAK3JAK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | claimed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| US-20080108633-A1 | Use 540 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | claimed |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4574214-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250195514-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-2914622-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2014071419-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080108633-A1 | Use 540 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195514-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | NTRK1 2894/4885AURKA 766/4885JAK3 1602/4885 |
| US-20150073036-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885AURKA 980/4885JAK3 2685/4885 |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | NTRK1 574/4885AURKA 156/4885JAK3 73/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | NTRK1 1066/4885AURKA 3234/4885JAK3 3043/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | NTRK1 1684/4885AURKA 4593/4885JAK3 2382/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | NTRK1 1138/4885AURKA 3122/4885JAK3 2956/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | NTRK1 1066/4885AURKA 3234/4885JAK3 3043/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | NTRK1 574/4885AURKA 156/4885JAK3 73/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | NTRK1 485/4885AURKA 146/4885JAK3 29/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | NTRK1 1138/4885AURKA 3122/4885JAK3 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.